Opus Enters Collaboration with Resilience for AAV-Based Gene Therapy Development and Manufacturing

Opus enters a strategic collaboration with Resilience for AAV-based gene therapy development and manufacturing for inherited retinal diseases.

Opus Genetics, a gene therapy company focused on inherited retinal diseases, announced on April 11, 2022 that it is entering a manufacturing services agreement with Resilience, a technology-focused biomanufacturing company, to support the development and manufacturing of Opus’ pipeline.

Resilience will provide process and analytical development, quality control testing, and good manufacturing practice manufacturing services for Opus’ adeno-associated viral (AAV) vector-based gene therapies for inherited retinal diseases for use in both preclinical studies and future clinical trials in the United States. This work will take place at Resilience’s facilities in Waltham, Mass., and Research Triangle Park, NC.

“Resilience embraces our innovative model to create a clinical manufacturing infrastructure that’s scaled to address rare inherited retinal diseases, and we are pleased to enter into this strategic collaboration,” said Ben Yerxa, PhD, CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, and acting CEO of Opus, in a press release. “Leveraging Resilience’s expertise puts Opus in the best position to efficiently advance our AAV-based gene therapies into the clinic and toward the patients who need them.”

“Helping Opus advance their gene therapies for inherited retinal diseases to the clinic will hopefully lead to new treatments for underserved patients,” said Rahul Singhvi, ScD, CEO of Resilience, in the release. “We’re excited to partner with Opus on process development and manufacturing at this pivotal time for the company.”

Source: Opus